| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |